Vor Bio announces positive clinical data for trem-cel + Mylotarg in AML; FDA agrees on registrational trial design

Vor Biopharma Inc.

Preliminary data shows median RFS not reached after 7.4 months follow-up in 15 AML patients treated with trem-cel + Mylotarg.
Engraftment achieved in 100% of patients: neutrophil engraftment median 9.5 days, platelet recovery median 16 days.
CD33 editing efficiency median 90% (range 71-94%); doses up to 2 mg/m2 without significant toxicity.
FDA agreed on registrational trial design for trem-cel + Mylotarg, including study population, control arm, primary endpoint.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.